| AACR Project GENIE: powering precision medicine through an international consortium AACR Project Genie Consortium, AACR Project GENIE Consortium, ... Cancer discovery 7 (8), 818-831, 2017 | 1232 | 2017 |
| Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials F Meric-Bernstam, L Brusco, K Shaw, C Horombe, S Kopetz, MA Davies, ... Journal of clinical oncology 33 (25), 2753, 2015 | 418 | 2015 |
| Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML CD DiNardo, F Ravandi, S Agresta, M Konopleva, K Takahashi, T Kadia, ... American journal of hematology 90 (8), 732-736, 2015 | 337 | 2015 |
| Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes RR Singh, KP Patel, MJ Routbort, NG Reddy, BA Barkoh, B Handal, ... The Journal of molecular diagnostics 15 (5), 607-622, 2013 | 335 | 2013 |
| Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes JM Loree, AAL Pereira, M Lam, AN Willauer, K Raghav, A Dasari, ... Clinical Cancer Research 24 (5), 1062-1072, 2018 | 313 | 2018 |
| Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics R Kanagal-Shamanna, BP Portier, RR Singh, MJ Routbort, KD Aldape, ... Modern pathology 27 (2), 314-327, 2014 | 220 | 2014 |
| Selective inhibition of kindling development by intraventricular administration of TrkB receptor body DK Binder, MJ Routbort, TE Ryan, GD Yancopoulos, JO McNamara Journal of Neuroscience 19 (4), 1424-1436, 1999 | 206 | 1999 |
| Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring R Luthra, KP Patel, NG Reddy, V Haghshenas, MJ Routbort, MA Harmon, ... Haematologica 99 (3), 465, 2014 | 201 | 2014 |
| A decision support framework for genomically informed investigational cancer therapy F Meric-Bernstam, A Johnson, V Holla, AM Bailey, L Brusco, K Chen, ... Journal of the National Cancer Institute 107 (7), djv098, 2015 | 199 | 2015 |
| Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) KT Flaherty, RJ Gray, AP Chen, S Li, LM McShane, D Patton, SR Hamilton, ... Journal of Clinical Oncology 38 (33), 3883, 2020 | 196 | 2020 |
| Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms SS Talwalkar, RN Miranda, JR Valbuena, MJ Routbort, AW Martin, ... The American journal of surgical pathology 32 (9), 1299-1309, 2008 | 196 | 2008 |
| Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib KP Patel, KJ Newberry, R Luthra, E Jabbour, S Pierce, J Cortes, R Singh, ... Blood, The Journal of the American Society of Hematology 126 (6), 790-797, 2015 | 194 | 2015 |
| Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol F Meric-Bernstam, L Brusco, M Daniels, C Wathoo, AM Bailey, L Strong, ... Annals of Oncology 27 (5), 795-800, 2016 | 182 | 2016 |
| Immunohistochemical evidence of seizure-induced activation of trk receptors in the mossy fiber pathway of adult rat hippocampus DK Binder, MJ Routbort, JO McNamara Journal of Neuroscience 19 (11), 4616-4626, 1999 | 176 | 1999 |
| Pancreatic and bile duct brushing cytology in 1000 cases: review of findings and comparison of preparation methods KE Volmar, RT Vollmer, MJ Routbort, AJ Creager Cancer Cytopathology: Interdisciplinary International Journal of the …, 2006 | 172 | 2006 |
| The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design KT Flaherty, R Gray, A Chen, S Li, D Patton, SR Hamilton, PM Williams, ... JNCI: Journal of the National Cancer Institute 112 (10), 1021-1029, 2020 | 163 | 2020 |
| Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 157 | 2019 |
| Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma AE Siroy, GM Boland, DR Milton, J Roszik, S Frankian, J Malke, L Haydu, ... Journal of Investigative Dermatology 135 (2), 508-515, 2015 | 157 | 2015 |
| Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases CY Ok, KP Patel, G Garcia-Manero, MJ Routbort, B Fu, G Tang, ... Leukemia research 39 (3), 348-354, 2015 | 144 | 2015 |
| Factors affecting the success of next‐generation sequencing in cytology specimens S Roy‐Chowdhuri, RS Goswami, H Chen, KP Patel, MJ Routbort, ... Cancer cytopathology 123 (11), 659-668, 2015 | 136 | 2015 |
Funda Meric-BernstamChair, Department of Investigational Cancer Therapeutics, The UT MD Anderson Cancer CenterAdresse e-mail validée de mdanderson.org
